Objective To investigate the clinical effect of supplemented Dabu Yuanjian combined with PEGylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in patients with grade III or IV myelosuppression after platinum-based doublet chemotherapy. Methods A total of 150 patients with grade III or IV myelosuppression after platinum-based doublet chemotherapy were selected and randomly divided into the control group or the study group, with 75 cases in each group. The control group was treated with PEG-rhG-CSF, based on which the study group was treated with modified Dabu Yuanjian additionally, and both groups continued the medication for 21 days. The blood routine examination indexes, T lymphocyte subsets, quality of life, and the incidence of adverse reactions during treatment were compared between the two groups. Results After 21 days of treatment, the leukocyte, neutrophil, CD3+, and CD4+ levels; CD4+/CD8+; and scores in 4 domains of the World Health Organization Quality of Life scale (physical health, psychological, social relationships, and environmental health) in the study group were higher than those in the control group, and the CD8+ level was lower than that in the control group (all P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups during treatment (P>0.05). Conclusion Supplemented Dabu Yuanjian combined with PEG-rhG-CSF can improve the blood routine examination results, correct T lymphocyte disorders, and improve the quality of life for patients with grade III or IV myelosuppression after platinum-based doublet chemotherapy. 

无